News&Media

2018-11-05 Gongwin-KY cancer new drug PTS mechanism of action has been awarded to internationally renowned journals

Taipei, November 05, 2018

Gongwin Biopharm Co., Ltd. (hereinafter referred to as “KY”, stock code: 6617) has long been focusing on the development of PTS anticancer drugs for “minimally invasive targeted tumor ablation therapy”, and has cooperated with domestic and foreign research teams since 2016. The mechanism of action of the new drug PTS. According to the results of this study, PTS causes abnormal metabolic pathways of cholesterol in cancer cells, interferes with the stability of Lipid raft structure, and blocks the transmission of proliferation, proliferation and metastasis of downstream cancer cells. In addition, tumor xenografts The model shows that the new drug PTS can inhibit tumor growth, and the tumor growth inhibition rate is 56%, indicating the anti-cancer effect in vivo. The results of this research have been accepted by the internationally renowned journal Frontiers in Pharmacology in October 2018, and the journal has been scheduled for follow-up dates. This research and development milestone of the letter-KY highlights the fact that its new drug PTS has been internationally recognized.

KY said that it is a leap from traditional cancer treatment thinking. Its new PTS drugs include PTS302, which includes severe airway obstruction in central lung cancer, PTS100 in primary liver cancer, PTS-02 in adenoid cystic carcinoma, and PTS500 in malignant pleural effusion. PTS drugs are directly injected into tumors and surrounding tissues using the technique of minimally invasive targeted tumor ablation. Therefore, the drugs will mainly concentrate on the tumor site and will not affect the surrounding normal tissues to achieve relative safety and effectiveness. the goal of. The new lung cancer drug PTS302 in the above four products has been submitted to China's New Drug Inspection Register (NDA) in 2017 and included in the priority review and approval. Optimistic about PTS302 under the pharmaceutical reform in China, if the drug is approved for marketing, it is expected to take the lead in paying attention to the overall operation of the company to show good growth momentum.

Looking forward to the future, KY is committed to implementing the strategic layout of Taiwan's R&D, China's marketing and multinational clinical research, and has targeted Taiwan, China, the United States, New Zealand and Australia to carry out various businesses. Not only is the new drug PTS302 in China's drug certification review available. Good progress; at the same time, it is also actively discussing cooperation memoranda with the clinical research centers of the United States, New Zealand and Australia.


News contact:

Gongwin Biopharm Deputy General Manager Xiao Sixin  (02)2503-5282  pierre@gongwinbiopharm.com

IR Trust   Senior manager  (02)2585-5701/0911770738   sherrytu@ir-trust.tw

About Gongwin Biopharm:

Founded in 2014, Gongwin Biopharm (Gongwin Biopharm Holdings Co., Ltd., stock code: 6617) is a biotechnology pharmaceutical company based in Taiwan, focusing on the development of new drugs for small molecule anticancer chemical ablation. Gongwin Biopharm breaks away from traditional cancer treatment thinking and combines minimally invasive surgery to develop new anticancer drugs with PTS as the main active ingredient, providing cancer patients with the option of directly eliminating tumors. PTS as a new drug development began in the 1980s. After years of research, the inventors Wu Yizhuang and Dr. Shi Jiaxuan completed the Phase III clinical trial of PTS-302 new drug for non-small cell lung cancer in 2011. And accelerate the application for a drug license to the Chinese CFDA.

In view of the maturity and energy and layout of Taiwan's R&D environment, PTS International Inc. established Gongwin Biopharm and Gongwin Holdings in Taiwan in 2014 and completed the integration and restructuring in December 2015. With Gongwin Biopharm, a subsidiary of Gongwin Holdings, as its operational headquarters, it promotes the Group's global drug research and development, clinical research, manufacturing technology, international licensing and marketing planning and promotion, based in Taiwan and looking to the world.

statement:

This document and related information published at the same time contain predictive statements. In addition to the facts that have occurred, all to Gongwin Biopharm
(
Hereinafter referred to as the company
)
The description of future business operations, possible events and prospects (including but not limited to forecasts, targets, estimates and operating plans) are predictive statements. Predictive narratives are subject to different factors and uncertainties, which are quite different from actual situations, including but not limited to price fluctuations, actual demand, exchange rate changes, market share, market competition, laws, finances and regulations. Changes in the structure, international economic and financial market conditions, political risks, cost estimates, etc., and other risks and variables outside the control of the company. These predictive statements are based on current forecasts and assessments, and the company is not responsible for future updates.